Phosphoserine has a potential as a neuroprotective agent in treating glaucoma patient

Nutraveris

This prospective randomized placebo-controlled clinical trial was conducted to evaluate the neuroprotective role of phosphoserine in primary open-angle glaucoma (POAG) patients.

To do so, 51 POAG patients were randomized to receive either 60 mg/100 mL of phosphoserine or placebo for 12 months in cycles of 14 consecutive days per month. Complete ophthalmological examination, standard automated perimetric examination, analysis of ON fibers via scanning laser polarimetry and glaucoma staging were performed in all patients at enrolment and 1, 3, 6, and 12 months after.

Results showed that a statistically significant improvement (p < 0.05) in visual fields, retinal nerve fiber layer thickness and intraocular pressure compared to pre-treatment was found in patients supplemented with phosphoserine.

Therefore, phosphoserine has a potential as a neuroprotective agent in treating glaucoma patient.

Scalinci SZ, Lugaresi M, Scorolli L, Ralli M, Greco A, Pantaleone V, Taurone S, Franzone F. Neuroprotective role of phosphoserine in primary open-angle glaucoma patients. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):9780-9786.

Photo by Luca Iaconelli on Unsplash

NOL Data Solution
NOL Compliance